Gilead says counterfeiting network sold $250 mln worth of its HIV drugs

Author of the article: Gilead Sciences Inc said on Tuesday that tampered and counterfeit versions of its HIV treatments worth $250 million were sold to pharmacies over two years by a network of drug distributors and suppliers. The drugmaker said in August that distributors not authorized by Gilead to sell its HIV treatments, Biktarvy and…
Gilead says counterfeiting network sold $250 mln worth of its HIV drugs

Author of the article:

Gilead Sciences Inc said on Tuesday that tampered and counterfeit versions of its HIV treatments worth $250 million were sold to pharmacies over two years by a network of drug distributors and suppliers.

The drugmaker said in August that distributors not authorized by Gilead to sell its HIV treatments, Biktarvy and Descovy, have sold counterfeits to pharmacies where genuine Gilead bottles have been tampered with a counterfeit foil induction seal or label and contain incorrect tablets.

“After becoming aware of counterfeit Gilead HIV medication being distributed we notified federal law enforcement authorities, including the FDA, as well as dispensing pharmacies, and then took direct and urgent legal action,” a Gilead spokesperson said on Tuesday.

Gilead said the distributors, against whom it had filed a lawsuit, had sold 85,247 bottles of counterfeit HIV drugs.

(Reporting by Manas Mishra in Bengaluru; Editing by Amy Caren Daniel)

Financial Post Top Stories

Sign up to receive the daily top stories from the Financial Post, a division of Postmedia Network Inc.

By clicking on the sign up button you consent to receive the above newsletter from Postmedia Network Inc. You may unsubscribe any time by clicking on the unsubscribe link at the bottom of our emails. Postmedia Network Inc. | 365 Bloor Street East, Toronto, Ontario, M4W 3L4 | 416-383-2300

Read More

Total
0
Shares
Leave a Reply

Your email address will not be published.

Related Posts
Fraser Institute News Release: Ottawa’s misguided Indo-Pacific trade strategy unlikely to succeed
Read More

Fraser Institute News Release: Ottawa’s misguided Indo-Pacific trade strategy unlikely to succeed

Author of the article:Published Oct 24, 2023  •  2 minute read VANCOUVER, British Columbia, Oct. 24, 2023 (GLOBE NEWSWIRE) — The federal government’s new Indo-Pacific trade strategy (IPS), meant to encourage increased Canadian exports to Indo-Pacific countries such as India and China through subsidies and other preferential treatments, unwisely shifts attention from Canada’s largest trading…